Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013 (EMA press release, 31 May 2013)

The European Medicines Agency (EMA) has published the latest news from its Committee for Medicinal Products for Human Use, including updates on Somatropin Biopartners for endogenous growth hormone deficiency, its review of new safety data on insulin glargine, an application to modify the approved use of Lysodren (mitotane) and a Q&A on withdrawal of the marketing authorisation application for Belviq (lorcaserin). Full article
Source: Society for Endocrinology - Category: Endocrinology Source Type: news